1Schneider J,Pollan M,Jimenez E,et al.nm23-H1 expression defines a highrisk subpopulation of patients with early-stage epithelial ovarian carcinoma.Br J Cancer,2000,82(10):1662-1667
2Baekelandt M,Holm R,Trope C,et al.The significance of mtastasisrelated factors cathpsin-D and nm23 in advanced ovarian cancer.Ann Oncol,1999,10(11):1335-1341
3Karlan BY,Baldwin RL,Lopez-Luevanos E,et al.Peritoneal serous papillary carcinoma,a phenotypic variant of familial ovarian cancer:implications for ovarian cancer screening.Am J Obstet Gyneeol,1999,180(4):917-928
4Scambia G,Ferrandina G,Marone M,et al.nm23 in ovarian cancer:correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters.J Clin Oncol,1996,14(2):334-342
5Alaiya AA,Franzen B,Fujioka K,et al.Phenotypic analysis of ovarian carcinoma:polypeptide expression in benign,borderline and malignant tumors.Int J Cancer,1997,73(5):678-683
6Rohlke P,Milde-Langosch K,Weyland C,et al.p53 is a persistent and predictive marker in advanced ovarian carcinomas:multivariate analysis including comparison with Ki67 immunoreactivity.J Cancer Res Clin Oncol,1997,123(9):496-501
7Sood AK,Sorosky jI,Dolan M,et al.Distant metastases in ovarian cancer:association with p53 mutions:Clin Cancer Res,1999,5(9):2485-2490
8Kanmura T,Sakai K,Kaku T,et al.Comparison of p53 and CD44 variant 6 expression between paired primary and recurrent ovarian can cer:an immunohistochemical analysis.Oncol Rep,1999,6(1):97-101
9Kim J,Hwang ES,Kim JS,et al.Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse.Cancer Gene Ther,1999,6(2):172-178
10Wan M,Li WZ,Duggan BD,et al.Telomerase activity in benign and malignant epithelial ovarian tumor.J Natl Cancer Inst,1997,89(3):437-441
